Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) has entered into a services agreement with Nanosoft Polymers to support the development of ONC010, the company's lead nanoparticle-formulated PNKP inhibitor. The collaboration is designed to strengthen the manufacturing and formulation foundation of ONC010 as it progresses through IND-enabling development and preparation for future clinical studies.
Under the agreement, Nanosoft will provide polymer process development, analytical characterization, formulation optimization, scale-up support, and technology transfer services for Onco's proprietary PEO-PBCL polymer platform. This work aims to establish scalable polymer production processes, enhance analytical methods, and support future GMP manufacturing readiness. The collaboration complements ongoing chemistry, manufacturing, and controls activities with Dalton Pharma Services and preclinical development efforts at Nucro-Technics as Onco advances ONC010 toward first-in-human clinical evaluation.
The importance of this announcement lies in the critical role that robust manufacturing and formulation processes play in bringing novel cancer therapies to patients. By engaging Nanosoft, Onco-Innovations is addressing key hurdles in drug development, such as scalability and analytical characterization, which are essential for regulatory approval and clinical success. ONC010, a nanoparticle-formulated PNKP inhibitor, represents a potential new approach to targeting solid tumors, and this partnership may accelerate its path to the clinic.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company has secured an exclusive worldwide license to patented technology that targets solid tumors. This collaboration with Nanosoft is a strategic move to de-risk the development program and ensure that ONC010 is manufactured to the highest standards required for clinical trials.
For investors, this development signals that Onco-Innovations is actively advancing its pipeline and addressing technical challenges early in the development process. The partnership with Nanosoft, a company with expertise in polymer science, could enhance the probability of success for ONC010. As the program moves toward IND-enabling studies, the establishment of scalable and reproducible manufacturing processes will be a key milestone. The latest news and updates relating to ONNVF are available in the company's newsroom at https://ibn.fm/ONNVF.
